UF team identifies novel targets for COVID-19 antivirals
A multidisciplinary team of UF researchers has identified dozens of novel therapeutic targets for the development of antiviral therapies against COVID-19. The team recently posted a paper to bioRxiv reporting the identification of 53 novel genes and pathways that could become druggable targets for antiviral therapies for COVID-19 plus a broad array of coronavirus types.
Principal investigator Michael Norris, Ph.D., molecular biologist and bioengineer in the College of Liberal Arts and Sciences, says that identifying new or repurposed therapeutics is critical due to the increasing impact of new genetic variants in the pandemic.